These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 16767916)
1. Cytoreduction and intraperitoneal chemotherapy for the management of non-gynecological peritoneal surface malignancy. Yan TD; Esquivel J; Carmignani P; Sugarbaker PH J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):109-17. PubMed ID: 16767916 [TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis. Nesher E; Greenberg R; Avital S; Skornick Y; Schneebaum S Isr Med Assoc J; 2007 Nov; 9(11):787-90. PubMed ID: 18085034 [TBL] [Abstract][Full Text] [Related]
3. Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. Sugarbaker PH Cancer Invest; 2005; 23(2):155-72. PubMed ID: 15813509 [TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study. Asero S; Caruso M; Vallone N; Luciani AG; Lombardo V; Terranova G; Ettore G; Giannone G In Vivo; 2009; 23(4):645-7. PubMed ID: 19567402 [TBL] [Abstract][Full Text] [Related]
5. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Begossi G; Gonzalez-Moreno S; Ortega-Perez G; Fon LJ; Sugarbaker PH Eur J Surg Oncol; 2002 Feb; 28(1):80-7. PubMed ID: 11869020 [TBL] [Abstract][Full Text] [Related]
6. Management of peritoneal carcinomatosis from colorectal cancer: current state of practice. Cotte E; Passot G; Mohamed F; Vaudoyer D; Gilly FN; Glehen O Cancer J; 2009; 15(3):243-8. PubMed ID: 19556911 [TBL] [Abstract][Full Text] [Related]
7. Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy. Sugarbaker PH Tech Coloproctol; 2005 Jul; 9(2):95-103. PubMed ID: 16007367 [TBL] [Abstract][Full Text] [Related]
8. [Updated treatment of peritoneal carcinomas: a review]. Deraco M; Laterza B; Kusamura S; Baratti D Minerva Chir; 2007 Dec; 62(6):459-76. PubMed ID: 18091656 [TBL] [Abstract][Full Text] [Related]
9. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150 [TBL] [Abstract][Full Text] [Related]
10. Treatment of pseudomyxoma peritonei with two times--cytoreduction and hypertermic antiblastic peritoneal perfusion (HAPP). De Simone M; Scuderi S; Vaira M; Costamagna D; Barone R; Fiorentini G; Dentico P; Caponi A; Ciaccio B; Caponi C; Ferri L; Martini E; Cantini S J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):25-8. PubMed ID: 16767902 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Sugarbaker PH Expert Opin Pharmacother; 2009 Aug; 10(12):1965-77. PubMed ID: 19563273 [TBL] [Abstract][Full Text] [Related]
12. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures. Smeenk RM; Verwaal VJ; Zoetmulder FA Eur J Surg Oncol; 2006 Mar; 32(2):186-90. PubMed ID: 16303281 [TBL] [Abstract][Full Text] [Related]
13. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience. Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401 [TBL] [Abstract][Full Text] [Related]
14. Ten years experience in the treatment of pseudomyxoma peritonei by cytoreduction, peritonectomy and semi-closed hyperthermic antiblastic peritoneal perfusion. De Simone M; Vaira M; Caponi A; Ciaccio B; Fiorentini G; Turrisi G; Ferri L; Buti G In Vivo; 2006; 20(6A):725-7. PubMed ID: 17203755 [TBL] [Abstract][Full Text] [Related]
15. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976 [TBL] [Abstract][Full Text] [Related]
16. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Mohamed F; Moran BJ Cancer J; 2009; 15(3):196-9. PubMed ID: 19556904 [TBL] [Abstract][Full Text] [Related]
17. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859 [TBL] [Abstract][Full Text] [Related]
18. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. Chua TC; Yan TD; Morris DL J Surg Oncol; 2009 Feb; 99(2):109-13. PubMed ID: 19016259 [TBL] [Abstract][Full Text] [Related]
19. A curative approach to peritoneal carcinomatosis from colorectal cancer. Sugarbaker PH Semin Oncol; 2005 Dec; 32(6 Suppl 9):S68-73. PubMed ID: 16399436 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]